Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors

Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors

Pancreatic ductal adenocarcinoma (PDAC) remains a very difficult cancer to treat. Recent in vitro and in vivo studies suggest that the activation of the receptor for advanced glycation end products (RAGE) by its ligands stimulates pancreatic cancer cell proliferation and tumor growth. Additional stu...

Full description

Bibliographic Details
Main Authors: Priyanka Swami, Kelly A. O’Connell, Swetha Thiyagarajan, Ayrianne Crawford, Prathamesh Patil, Prakash Radhakrishnan, Simon Shin, Thomas C. Caffrey, James Grunkemeyer, Tammi Neville, Stefan W. Vetter, Michael A. Hollingsworth, Estelle Leclerc
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Biomolecules
Subjects:
RAGE
pancreatic cancer
gemcitabine
cachexia
Online Access:https://www.mdpi.com/2218-273X/11/4/526

Internet

https://www.mdpi.com/2218-273X/11/4/526

Similar Items